Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. Three such inhibitors, palbociclib, ribociclib, and abemaciclib were recently approved for breast cancer treatment in vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Braal, C. Louwrens, Jongbloed, Elisabeth M., Wilting, Saskia M., Mathijssen, Ron H. J., Koolen, Stijn L. W., Jager, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952354/
https://www.ncbi.nlm.nih.gov/pubmed/33369721
http://dx.doi.org/10.1007/s40265-020-01461-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952354/
https://www.ncbi.nlm.nih.gov/pubmed/33369721
http://dx.doi.org/10.1007/s40265-020-01461-2

Ejemplares similares